Researchers examine efficacy, safety of at-home abortion pills

A recent report by The New York Times follows the story of a woman who opted for a medicine-induced abortion in her home on her own terms.

“I was happy that I was going to be able to do it myself, and I did not have a nurse there or doctors there staring at me and judging me,” said Marie, identifying only by her middle name.

She is part of a research effort to examine how effective and safe a medicine induced abortion can be done through online consultations and drugs mailed to a patient’s home.

Though some find the concept dangerous and disturbing, other says it could be a good option for women at a time when access to abortion is limited.

To read more about the option, follow the link below.

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.